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*e present study describes a patient aged 70 with very high-risk AML who successfully received a nonmyeloablative matched
unrelated donor allograft shortly following SARS-CoV-2 infection, which manifested with mild cough, interstitial abnormalities
on chest CT, and pancytopenia with profound bone marrow biopsy histological alterations. In parallel, our study provides bone
marrow biopsy data in a series of contemporary patients with serious haematological diseases who had a bone marrow biopsy
performed within two weeks of PCR confirmation of SARS-CoV-2 infection. *is study is notable because there are no published
data describing the bone marrow biopsy changes observed in patients with haematological malignancies and SARS-CoV-2
infection. Finally, it is suggested that nonmyeloablative hematopoietic stem cell transplantation for very high-risk haematological
malignancies can be successfully performed following recovery from SARS-CoV-2 infection.
1. Case Report
Corona virus disease 2019 (COVID-19), which is caused by
the severe acute respiratory syndrome corona virus 2
(SARS-CoV-2), has infected millions of people all over the
world and over one million deaths reported [1].
Individuals infected by SARS-CoV-2 experience a broad
spectrum of symptoms, ranging from mild respiratory symp-
toms to severe respiratory and multiorgan failure [2]. Patho-
logical findings precipitated by the SARS-CoV-2 virus are under
intense study, but there is a paucity of data with regards to bone
marrow involvement [3]. Herein, we describe the case of a 70-
year-old female patient with acute myeloid leukaemia (AML)
who had clinically mild COVID-19 infection pretransplant,
which resulted in new onset cytopenias and novel bonemarrow
morphological changes in the absence of disease relapse.
*e patient was diagnosed with AML with myelodys-
plastic changes based on myelodysplastic syndrome-
(MDS-) related cytogenetic features but with no morpho-
logical evidence of dysplasia in December 2019. She had no
significant comorbidities. *e immunophenotype of the
neoplastic cells at diagnosis was CD34+/CD117+/CD13+/
HLA-DR+/nTdt+/CD33-/MPO weak. *e karyotype and
next generation sequencing panel showed an abnormal
karyotype with trisomy13/add(17p) and clinically significant
variants in ASXL1, RUNX1, IDH2, and BCOR, respectively.
*e patient was treated with two cycles of CPX-351
(liposomal cytarabine/daunorubicin), which were com-
pleted in February 2020 and resulted in complete remission.
Bone marrow biopsy after cycle two of induction chemo-
therapy showed prominent postchemotherapy damage and
dysplastic megakaryocytes but no excess of blasts, consistent
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with a dysplastic remission. Karyotype was normal, con-
sistent with cytogenetic remission. *e complete blood
count (CBC) at that time was Hb 85 g/L, WBC 4.34×109/L,
neutrophils 1.24×109/L, and platelets 85×109/L.
Based on the very high-risk genetic profile and taking
into account patient fitness and preference, a fully matched
volunteer unrelated donor (MUD) hematopoietic stem cell
transplant, conditioned with fludarabine/cyclophospha-
mide/total body irradiation 2Gy with post-transplant cy-
clophosphamide/tacrolimus/mycophenolate mofetil for
primary graft versus host disease prophylaxis, was deployed
for consolidation due to the high-relapse risk and the low
rates of chronic graft-versus-host disease observed with this
T-replete nonmyeloablative conditioning regimen [4].
*e patient had a screening nasopharyngeal swab for
SARS-CoV-2 before the planned admission date for the
transplant, which was reported as positive. *e transplant
was therefore postponed. Apart from mild fatigue and mild
dry cough, the patient did not report significant symptoms.
CRP was only mildly elevated, peak level recorded 39mg/L.
Over the next two weeks, the patient became more pan-
cytopenic and required transfusion support with packed red
cells and platelets (CBC at the end of April: Hb 67 g/L, WBC
2.30×109/L, neutrophils 0.81× 109/L, and platelets 7×109/
L). Repeat bone marrow biopsy showed no evidence of
relapse, but accentuated myelodysplasia-related findings
including striking erythroid hyperplasia, megaloblastic
features (folate 2.4 µg/L and vitamin B12 371 ng/L), extreme
“stress-type” arrangement of erythroid cells, myeloid sup-
pression, reduced numbers of megakaryocytes with mega-
karyocytic atypia, and increased histiocytes (confirmed on
CD163 and CD68/PGM1 immunostaining) in conjunction
with other features of stromal damage, consistent with very
pronounced toxic-type injury (Figure 1). *e aspirate
showed abundant foamy macrophages with markedly re-
duced megakaryocytes, some haemophagocytosis, and mild
erythroid dysplasia. Liver function tests confirmed elevated
bilirubin and ferritin at 31 µmol/L and 1854 ng/mL, re-
spectively, with normal enzymes. *e patient was afebrile
and did not have any organomegaly. *e karyotype was
normal. Serology was negative for HIV, hepatitis B/C/E, and
oarvovirus, whereas the patient was negative for EBV and
CMV by PCR. PT was only mildly prolonged at 15 seconds
and APTT was never prolonged; D-dimer and fibrinogen
were not measured. High resolution CT scan of the chest
demonstrated bilateral air space opacities, with ground glass
changes and interlobular septal thickening in the right lower
lobe. *e patient underwent bronchoalveolar lavage which
did not isolate any other viral, fungal, or bacterial pathogen.
In all, there were neither respiratory sequelae (other than the
mild cough), nor any need to treat with remdesivir or
steroids, as repeat SARS-CoV-2 nasopharyngeal swabs were
negative and there was improvement in the findings in the
follow-up high resolution CT scan of the chest. *e patient
therefore proceeded with the planned nonmyeloablative
MUD allogeneic stem cell transplant. *e peritransplant
period was complicated by a single episode of culture
negative febrile neutropenia and delayed engraftment
(neutrophils-platelets engrafted on days +25 and +45,
respectively). *e patient remains well, disease-free (100%
chimerism), without infective concerns, or active GvHD as
of the time of writing this report, on day +180 out from
transplant.
2. Discussion
*is case describes an individual who was incidentally di-
agnosed with SARS-COV-2 infection before a planned bone
marrow transplant for high-risk AML with MDS-related
changes. At the time of SARS-CoV-2 infection, the patient
was in complete remission with near normal counts, but the
virus triggered new onset transfusion-dependent cytopenias.
*e transplant was therefore deferred by four weeks. Bone
marrow biopsy two weeks after SARS-COV-2 infection
diagnosis revealed marked changes (i.e., exacerbated dys-
plasia in hematopoietic cells, abundant histiocytes, and toxic
stromal changes). To date, there are no data from patient
series with regards to SARS-CoV-2-induced bone marrow
biopsy changes although there have been scant data about
bone marrow haemophagocytosis in bone marrow aspirates
in patients with severe SARS-CoV-2 infection [5].
*e haematological manifestations in patients with
symptomatic SARS-CoV-2 infection have been widely re-
ported and include leukopenia with lymphopenia and mild
thrombocytopenia. However, the exact mechanisms causing
these cytopenias are unclear and might involve both pe-
ripheral destruction/consumption and medullary dysfunc-
tion [6].
Cytopenias may be caused by a reduction in CD34+ cells,
which may occur due to a variety of mechanisms. *e
SARS-CoV-2 virus can bind to the ACE2 receptor on the
surface of hematopoietic cells and be internalized into
CD34+ cells, resulting in viral replication and apoptosis.*is
process may be facilitated by CD13 and CD66a (EACAMIa)
receptors, which are present on the surface of human bone
marrow CD34+ cells. It has been also proposed that auto-
antibodies targeting CD34+ bone marrow cells may be
produced in some individuals with SARS-CoV-2 infection
[7, 8]. SARS-CoV-2 may also affect bone marrow stromal
cells, leading to an altered bone marrow microenvironment.
Patients with severe SARS-CoV-2 infection experience an
excessive inflammatory response characterized by high levels
of cytokines, profound lymphopenia, and substantial
mononuclear cell infiltration in the lungs, heart, spleen lymph
nodes, and kidneys [9]. Destruction of bone marrow pro-
genitor cells by the cytokine storm could overwhelm the rate
of blood cell production, resulting in cytopenias [10]. Mac-
rophages are key players as they can be evaded directly by the
virus and activated by inflammatory signals, such as type I
interferon, with recruitment to inflamed tissues via chemo-
kine receptor CCR-2 [11, 12]. *is explains the accumulation
of histiocytes and stromal abnormalities observed in this
patient’s bone marrow biopsy after infection with the SARS-
CoV-2 virus. Similar changes also were observed in two other
patients in our centre who were diagnosed with COVID-19 as
discussed in Table 1 (patient number six who died of COVID-
19 after BEAM-autologous stem cell for nodular lymphocyte
predominant Hodgkin lymphoma and case two with newly
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Figure 1: Bone marrow biopsy findings before and after COVID-19 diagnosis. (a) Before SARS-CoV-2 detection, all three main he-
matopoietic lineages were visible. *ere was no significant dysplasia. Erythroid cells were relatively scant and scattered. *ere was subtle
stromal damage. (b) Following SARS-CoV-2 infection, prominent erythroid hyperplasia and signs of stromal damage were observed. Large
clusters of erythroid cells were locally synchronised at the same maturational stage (“stress erythropoiesis”). Proerythroblasts showed
megaloblastoid features. Erythroid cells approached the trabecular bone. (c) An excess of stromal histiocytes on CD163 immunostaining
after SARS-CoV-2 infection. (d) On CD61 immunostaining, profound megakaryocytic deficit and atypia were illustrated after SARS-CoV-2
infection.
Table 1: Characteristics of haematology patients with SARS-CoV-2 infection who had simultaneous bone marrow biopsy.
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Table 1: Continued.
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diagnosed blastoid plasma cell myeloma who also developed
severe thrombocytopenia amidst velcade/thalidomide/dexa-
methasone induction treatment). *e remaining patients
described in Table 1 had newly diagnosed haematological
disorders and the causative role of the SARS-CoV-2 infection
in their abnormal bone marrow histology is felt less likely.
*e patient described in this report had been diagnosed
with high-risk AML with MDS-related changes *e bone
marrow microenvironment in MDS is characterized by
higher levels of inflammatory cytokines and upregulation of
cell surface receptors for proinflammatory molecules [13],
such as TGF-beta, IL-1-beta and, danger-associated mo-
lecular pattern (DAMP) proteins.*erefore, the “dysplastic”
hematopoietic progenitor cells and their bone marrow niche
inflicted severe dysfunction during an otherwise mild
COVID-19.
*e immunocompromised nature of patients with
haematological malignancies, including patients undergoing
allogeneic stem cell transplantation, could have a negative
impact on clearance of the SARS-CoV-2 virus. On the other
hand, it might play an important role in later phases of the
disease, by regulating inflammatory processes [14].
*ere is a dilemma regarding the appropriate manage-
ment of transplant candidates who have been infected with
the SARS-CoV-2 virus as there is insufficient evidence to
support whether stem cell transplantation should be post-
poned or not. *e European Society for Blood and Marrow
Transplantation (EBMT) recommendations advise that
deferral of the transplant procedure should be considered
in patients who are PCR positive for SARS-CoV-2 in-
fection [15]. However, they acknowledge that this decision
should be individualised, taking into account the risk of
Table 1: Continued.
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progression of the underlying disease. *ey advise that
patients with high risk disease who have tested positive for
SARS-CoV-2 should have their transplant procedure
deferred for a minimum of 14 days and that they should be
asymptomatic and have had two negative PCR tests for the
SARS-CoV-2 virus that have been taken at least 24 hours
apart [15]. In keeping with this guidance, the transplant
procedure was deferred by four weeks in the case de-
scribed in this report. We proceeded once PCR negativity
for SARS-CoV-2 infection was confirmed and the CT
changes were resolving [15].
3. Conclusion
To the best of our knowledge, this is the first report fo-
cusing on bone marrow architectural changes in the
context of SARS-CoV-2 infection, in addition to the
feasibility of proceeding to a nonmyeloablative allogeneic
stem cell transplant with post-transplant cyclophospha-
mide for an elderly individual with high-risk AML less
than one month following SARS-CoV-2 infection. Our
report describes how the virus might precipitate marked
bone marrow pathology in patients predisposed to in-
flammatory bone marrow states ( e.g., postchemotherapy
or in myelodysplasia). In view of the very limited number
of patients and the heterogeneity of haematological di-
agnoses of the patients described in this report, further
multicentre clinical studies are warranted to best evaluate
the bone marrow changes induced by SARS-CoV-2 in-
fection and to inform the optimal peritransplant man-
agement of patients with recent SARS-CoV-2 infection.
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